摘要
目的探讨时间分辨荧光免疫检测技术（DELFIA）在孕中期唐氏综合征筛查中的应用。方法收集767例妊娠妇女孕中期血清标本，应用DELFIA进行AFP和Free-HCGβ的定量检测，当血清中AFP、HCG筛查风险系数大于或等于1／275时定为唐氏综合征高危妊娠（或筛查阳性）；染色体检查用英国CV-100染色体图像分析系统进行G带分析。结果（1）767例妊娠妇女中检出唐氏综合征高危孕妇36例，阳性率为4．69％，其中有32例孕妇自愿接受了产前诊断，有4例证实为唐氏综合征。（2）4例唐氏综合征，AFP浓度在0．05-0．21（〈0．5MoM），Freep—HCGB浓度在2．73～4．27之间（〉2．5MoM），均为21-三体综合征。结论采用DELFIA联合检测AFP和Free-HCGβ可以评估胎儿患唐氏综合征的风险，显著降低需进行创伤性产前诊断的孕妇比例，是目前较为可行、容易被孕妇接受的唐氏综合征产前筛查技术。
Objective To explore the application value of dissociation enhanced lanthanide fluoroimmunoassay （DELFIA） in the Down＇s syndrome prenatal screening on middle period pregnancy. Methods AFP and Free-HCGβ of 767 cases were quantitatively detected by DELFIA. Serum AFP, HCG screening risk values was 1/275, the pregnant women whose value was higher than or equal to 1/275 would be at high risk G-banding was analyzed for the chromosome determination by British CV-100 chromosome image analysis system. Results （1） 36 cases in 767 pregnant women were screened With high risk for Down＇s syndrome,with positive rate of 4.69% ,and 4 cases were verified as trisomy 21 through prenatal diagnosis who accepted amniocentesis. （2） In 4 cases of Downr s syndrome,AFP concentrations were between 0.05 to 0.21 （〈0.5MoM）, and Freep-HCGβ concentrations between 2.73 to 4.27 （〉2.5MoM）. Conclusion Combined tests of AFP and Free-HCGβ using DELFIA may be an effective and easily-accepted technique for Down＇s syndrome screening to the first trimester and second trimester pregnant women.
出处
《重庆医学》
CAS
CSCD
北大核心
2009年第1期70-72,共3页
Chongqing medicine
